natgillin/translations-raw huggingface dataset:
The pharmaceutical composition for use according to any of claims 1-3 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 1b and the crosslinked amine polymer is prepared by substitution polymerization of the amine corresponding to Formula 1 b with a polyfunctional crosslinker: wherein R4 and R5 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl, R6 is aliphatic and R61 and R62 are independently hydrogen, aliphatic, or heteroaliphatic. 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 1b i umreženi aminski polimer je dobiven supstitucijskom polimerizacijom amina koji odgovara formuli 1b s polifunkcionalnim sredstvom za umrežavanje:
Apparatus according to claim 13 or claim 14, adapted such that contact with the oxidation catalyst is controlled by the oxygen monitor such that the oxygen content of the off-gas after contact with the oxidation catalyst is within the range 1-16%. 
Uređaj prema zahtjevu 13 ili zahtjevu 14, prilagođen tako da se kontakt s oksidacijskim katalizatorom kontrolira putem monitora kisika tako da se sadržaj kisika u oslobođenom plinu nakon kontakta s oksidacijskim katalizatorom kreće u rasponu od 1-16%.
The method according to claim 11, wherein a second draw string is attached to the cleaning element so that pulling of the cleaning element through the outer sheath also pulls said second draw string through the outer sheath. 
Postupak sukladno zahtjevu 7, pri čemu se za element za čišćenje pričvršćuje druga rastezljiva uzica, pa se provlačenjem elementa za čišćenje kroz vanjski plašt (6) kroz njega provlači i navedena druga uzica.
The invention furthermore relates to a pharmaceutical composition comprising an effective amount of at least one compound according to the invention and/or one of its physiologically acceptable derivatives, salts, solvates, tautomers and/or stereoisomers thereof, including mixtures thereof in all ratios, optionally together with at least one pharmaceutically tolerated adjuvant or optionally an excipient and/or adjuvant. 
Farmaceutski pripravak naznačen time što sadrži učinkovitu količinu najmanje jednog spoja prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer ili stereoizomer, po izboru zajedno s najmanje jednom farmaceutski podnošljivom pomoćnom tvari. Farmaceutski pripravak prema zahtjevu 9, naznačen time što nadalje sadrži najmanje jedno antikancerogeno sredstvo.
Suitable viscosity-increasing agents for use in accordance with this aspect of the invention include, but are not limited to, polyvinylpyrrolidones (PVP) (preferably having a molecular weight of about 10,000 to about 360,000, as well as mixtures containing one or more grades or molecular weight of PVP), cellulose derivatives (including, but not limited to, hydroxyethyl cellulose, carboxymethyl cellulose or its salts, hypromellose, and the like), carrageenan, guar gum, alginates, carbomers, polyethylene glycols, polyvinyl alcohol, xanthan gum, and the like. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pripravak formuliran za okularnu primjenu. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni pripravak sadrži najmanje jedno sredstvo za povećavanje viskoznosti, koje se bira iz skupine koju čine polivinilpirolidon, celulozni derivat, kojeg se bira iz skupine koju čine hidroksietilceluloza, karboksimetilceluloza i hipromeloza, karagenan, guar guma, alginat, karbomer, polietilen-glikol, polivinil-alkohol i ksantanska guma, koje smanjuje ili sprječava postnazalno cijeđenje navedenog pripravka u ždrijelo prilikom intranazalne ili okularne primjene pripravka.
An immunogenic or vaccine composition comprising an isolated polypeptide having at least 85% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 and a pharmaceutically acceptable carrier or excipient, wherein the sequence identity is determined by Needleman-Wunsch global alignment. 
HR P20170193 T1 PATENTNI ZAHTJEVI Imunogenični sastav 1li cjepivo sadrži izolirani polipeptid koji ima najmanje 85% identičan slijed aminokiselinskom slijedu kako je navedeno u SEQ ID NO:4 i farmaceutski prihvatljivi nosač ili ekscipijens.
reacting a compound of formula VII with sodium acetate to produce a compound of formula VI 
b) reakcija spoja formule VII s natrijevim acetatom, da se proizvode spoj formule VI:
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence 
MOLEKULARNI GENETIČKI PRISTUP LIJEČENJU I DIJAGNOZI OVISNOSTI O ALKOHOLU I DROGAMA
The compound of Formula I: wherein 
Spoj, naznačen time, da ima formulu I:
a carboxamide group, or a pharmaceutically acceptable salt thereof. 
< a ili njegova farmaceutski prihvatljiva sol.
iii) applying an electric field over the membrane stack; 
III. primjenu električnog polja na stog membrana;
parse a merge flag from a video bitstream and decoding the merge flag only if sharing of the loop filter information is determined to be allowed, wherein the merge flag indicates whether the loop filter information is shared between the current block and the neighboring block. 
Postupak prema patentnom zahtjevu 8, pri čemu se spomenuto određivanje da li treba dopustiti dijeljenje podataka o filteru petlje između tog bloka i njemu susjednog bloka prema uvjetu omogućava ili onemogućava temeljem oznake upravljanja.
In this closed state of the extraction module a relatively low force driven from the motor 12 will cause a very high down-force of the respectively lower lever 19 of each pairs of levers 19. 
U tom zatvoreno položaju modula za ekstrakciju relativno mala sila dovedena od motora 12 će uzrokovati veliku silu prema dolje odgovarajuće donje poluge 19 svakog para poluga 19.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of Claims 1 to 8. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T limfocita (CTL), pri čemu se metoda sastoji od in vitro doticaja CTL-a s uklopljenim antigenima MHC molekula razreda II, prikazanim na površini prikladne stanice koja prikazuje antigen u vremenskom razdoblju dovoljnom za aktivaciju spomenutog CTL-a na antigen-specifičan način, gdje je spomenuti antigen peptid iz bilo kojeg od Zahtjeva 1 ili 2.
The composition of claim 2, which is further carbamated successively with PA and CC to obtain PA or CC terminated PHU chemically grafted on collagens, elastins, keratins, fibronectins, actins, myosins, laminins, peptides or a blend of those proteins or peptides, hydrolyzed, fibrillated or not. 
Sastav prema bilo kojem od zahtjeva 2, 3-5, 16 ili 17, koji je nadalje karbamatiran sukcesivno s PA 1 CC kako bi se dobili PA ili CC terminirani PHU kemijski cijepljeni kolageni, elastini, keratini, fibronektini, aktini, miozini, laminini, peptidi ili mješavina navedenih proteina ili peptida, hidroliziranih, fibriliranih ili ne.
Additionally, to the extent permitted by applicable patent statues and regulations, all publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety to the same extent as if each document had been individually incorporated by reference herein. A compound of formula I: where: a is 0, 1, 2, 3, or 4; each R1 is independently halo or trifluoromethyl; R3 is hydrogen, halo, or —C1-6alkyl; R4, R5, and R6 are independently hydrogen or halo; or a pharmaceutically acceptable salt thereof. 
Spoj Formule 1: či ili njegova sol, naznačen time da je: L bromo, jodo, ili-OS(O>)-R, gdje je R-C,alkil ili fenil, a fenil je po izboru supstituiran s -C,valkil, halo ili nitro; a je 0, 1, 2, 3, ili 4, svaki R' je neovisno halogen ili trifluorometil, a P je amino-zaštitna skupina odabrana iz t-butoksikarbonil, tritil, benziloksikarbonil, 9-fluorenilmetoksikarbonil, formil, trimetilsilil 1 t-butildimetilsilil.
the hybridoma of claim 12, wherein said hybridoma produces an antibody that inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Hibridom prema zahtjevu 12, gdje taj hibridom proizvodi protutijelo koje inhibira vezanje HLA-c alel molekule, koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
reacting the compound according to formula (10), or salt thereof, wherein R5 is hydrogen or alkyl, under ring-closing conditions to obtain a compound according to formula (1), or salt thereof. 
e) reakcija spoja prema formuli (10) ili njegove soli, pri čemu RS je vodik ili alkil, pod uvjetima zatvaranja prstena, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
the at least one active immunogenic component is derived from a pathogen comprising Adenoviridae, Parvoviridae, Coronaviridae, Herpesviridae, Poxvirididae, Rhabdoviridae, or combinations thereof or 
(a) najmanje jedna aktivna imunogena komponenta porijeklom je od patogena koji sadrži Adenoviridac, Parvoviridae, Coronaviridae, Herpesviridae, Poxvirididae, Rhabdoviridac ili njihove kombinacije ili
The method of claim 1 wherein said recovered unchanged (R)-2-isobutyl-succinonitrile of step (b) is racemized into racemic 2-isobutyl-succinonitrile by heating with a base in a solvent. 
Postupak u skladu s patentnim zahtjevom 1, gdje navedeni nepromijenjeni (R)-2-izobutilsukcinonitril iz koraka (b) se racemizira u racemični 2-izobutilsukcinonitril grijanjem s bazom u otapalu.
Use of an antibody or antigen-binding fragment of an antibody according to any one of claims 1 to 4 in the manufacture of a medicament for use in a method of attenuating or inhibiting an NGF-mediated disease or condition in a human selected from inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, gout joint pain, post-herpetic neuralgia, pain resulting from bums, cancer pain, osteoarthritis or rheumatoid arthritis pain, sciatica, pain associated with sickle cell crises, or post-herpetic neuralgia. 
Uporaba antitijela ili fragmenta koji veže antigen antitijela u skladu s bilo kojim od patentnih zahtjeva 1 do 4 naznačen time, da se koristi u proizvodnji lijeka za uporabu u postupku za smanjivanje ili inhibiranje stanje ili bolesti posredovanih NGF-om kod čovjeka odabranih između upalne boli, postoperativne boli uslijed operativnih rezova, neuropatske boli, boli uzrokovane lomom, kostobolje u zglobovima, post-herpetične neuralgije, boli uzrokovane opeklinama, boli uzrokovane karcinomom, boli uzrokovane osteoartritisom i reumatoidnim artritisom, išijas, bol povezanu s krizom srpastih stanica, ili post-herpetičke neuralgije.
The method according to embodiment 23, wherein the a-synuclein-related disorder is selected from the group consisting of Parkinson's disease, dementia with Lewy bodies and/or Lewy neurites, Alzheimer's disease, Down's syndrome, Multiple Systemic Atrophy (MSA), other diseases with Lewy body pathology, Alzheimer's disease syndrome, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, prion disease, Creutzfeldt Jakob's disease, Gerstmann-Sträussler-Scheinker syndrome, kuru, fatal familial insomnia, cerebrovascular amyloidosis, glaucoma, age-related macular degeneration, psychiatric syndromes, schizophrenia and schizophrenia-like disorders. 
Lijek za uporabu prema zahtjevu 1 ili 2, pri čemu je poremećaj vezan uz a-sinuklein odabran iz skupine koja se sastoji od Parkinsonove bolesti, demencije s Lewyjevim tjelešcima i/ili Lewyjevim neuritima, Alzheimerove bolesti, Downovog sindroma, multiple sistemske atrofije (MSA), drugih bolesti s patologijom Lewyjevih tjelešaca i sindroma Alzheimerove bolesti.
The use of claim 8, wherein the use is for providing local analgesia, local anesthesia or nerve blockade in a human following benign abdominal or thoracic surgical procedures. 
Uporaba u skladu s patentnim zahtjevom 9, pri čemu je uporaba za omogućavanje lokalne analgezije, lokalne anestezije ili blokade živca kod čovjeka nakon benignih abdominalnih ili torakalnih kirurških zahvata.
The therapeutic nanoparticle of claim 2, wherein the poly(lactic) acid-poly(ethylene)glycol copolymer has a number average molecular weight of 16kDa poly(lactic acid) and a number average molecular weight of 5kDa poly(ethylene)glycol. 
Terapeutska nanočestica prema zahtjevu 2, naznačena time da kopolimer poli(ćmliječna) kiselina-poli(etilen)glikol ima iznos prosječne molekularne težine od 16kDa poli(mliječna kiselina) i iznos prosječne molekularne težine od 5kDa poli(etilen)glikola.
the costimulatory 4-1BB signaling region comprises the amino acid sequence of SEQ ID NO:23; 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
An antibody that binds human CD3 which antibody comprises a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: with 0-10, preferably 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein 
Protutijela koje vežu humani CD3, protutijela koje sadrži teški lanac i laki lanac, naznačeno time, da navedeni teški lanac sadrži varijabilnu regiju koji sadrži aminokiselinsku sekvencu:
A method for reducing nocturnal urine volume in a patient in need thereof comprising: administering to the patient prior to bedtime an orodispersible dose of desmopressin of 10 [mu]g, wherein the dose is measured as the free base of desmopressin and the dose taken over a treatment period reduces the patient's nocturnal urine volume. 
Pripravak koji sadrži dezmopresin za uporabu u liječenju nokturije ili noćne poliurije za povećanje početnog razdoblja nesmetanog spavanja kod ženskog pacijenta kojem je potreban, naznačen time da pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina pri čemu se doza mjeri kao slobodna baza dezmopresina i koja se daje pacijentu prije spavanja.
The method according to claim 2 wherein a solution comprising an initial concentration of the therapeutic protein between about 0.3 mg/ml and about 3.0 mg/ml is adjusted to a pH value between about 5.0 and about 8.0 prior to contacting with the activated water soluble polymer; for example, wherein the initial concentration of the therapeutic protein is about 1.0 mg/ml and the pH is about 6.0. 
Postupak prema zahtjevu 2, pri čemu je otopina koja sadrži početnu koncentraciju terapeutskog proteina između oko 0.3 mg/ml 1 oko 3.0 mg/ml prilagođena na pH vrijednost između oko 5.0 1 oko 8.0 prije kontaktiranja s aktiviranim polimerom topljivim u vodi; na primjer, pri čemu je početna koncentracija terapeutskog proteina oko 1.0 mg/ml 1 pH je oko 6.0.
The method according to claim 1 characterized in that depending of the type and volume of the detached massif (1), holes with height H = 0.7-5 m are drilled, and gas-generating devices (8') are placed on one, two, or three levels (21, 22, and 23). 
Postupak prema zahtjevu 1, naznačen time, da u ovisnosti o vrsti i volumenu odvojenog masiva (1), rupe se buše u visini H = 0,7-5 m, a uređaji za stvaranje plina (8') se polažu na jednu, dvije 1li tri razine (21, 22 123).
means for processing the data delivered by said detecting and/or monitoring means and for determining the clotting time of said fluid medium, wherein the optical means also measure or read the quality control features on the microfluidic device. 
- uređaja za obradu podataka koje daje navedeni uređaj za detekciju i/ili praćenje i za određivanje vremena koagulacije navedenog fluidnog medija, gdje navedeni optički uređaj također mjeri ili očitava karakteristike kontrole kvalitete u mikrofluidičkom uređaju.
More preferably A3 is 
A3 se bira između
A method of detecting human Jaggedl in a biological sample comprising contacting the biological sample with the antibody of any one of claims 1 to 17, 29, and 30 under conditions permissive for binding of the antibody to a naturally occurring human Jagged1, and detecting whether a complex is formed between the antibody and a naturally occurring human Jaggedl in the biological sample. 
Postupak detekcije humanog Jagged1 u biološkom uzorku, naznačen time, da se sastoji od doticaja biološkog uzorka s protutijelom prema bilo kojem od patentnih zahtjeva 1 do 17, 29 1 30, pod uvjetima koji dopuštaju vezanje protutijela na humani Jagged1 koji se prirodno pojavljuje, i od otkrivanja da li je ostvaren kompleks u biološkom uzorku između protutijela 1 humanog Jagged1 koji se prirodno pojavljuje.
Another patent encountered is the patent application no. 
Datum podnošenja europske prijave patenta:
wherein said HDAC inhibitor is: and wherein said pharmaceutical composition is an aqueous liquid. 
pri čemu je spomenuti HDAC inhibitor: [image] i pri čemu spomenuti farmaceutski sastav je vodena tekućina.
To a round bottom flask was added water (170 ml) and hydrazine dihydrochloride salt (41.9 gm, 398.8 mmol). 
U tikvicu okruglog dna dodani su voda (170 mL) i sol hidrazin dihidroklorid (41.9 mg, 398.8 mmol).
or a pharmaceutically acceptable salt of any of the foregoing. 
Spoj 109, ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
when the upper SAO merging information indicates that the SAO parameters of the current block are determined according to SAO parameters of an upper block, the SAO parameter obtainer determines the SAO parameters of the luma component of the current block to be identical to SAO parameters of a luma component of the upper block, and the SAO parameters of the chroma components of the current block to be identical to SAO parameters of chroma components of the upper block, 
kada lijeva informacija SAO spajanja označava da su parametri SAO trenutnog bloka određeni prema parametrima SAO lijevog bloka, određivanje parametara SAO komponenata luminancije trenutnog bloka kako bi bili identični parametrima SAO komponenata luminancije lijevog bloka, i parametri SAO komponenata krominancije trenutnog bloka kako bi bili identični parametrima SAO komponenata krominancije lijevog bloka;
In another embodiment, in formula (VII), X42 is CR44, and R43 and R44, taken together with the carbon atoms to which they are attached, form a cycloalkenyl, aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 34, pri čemu X» je CRa 1 Rag i Ra, uzeti zajedno sa ugljikovim atomima za koje su vezani, čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
An inserter according to claim 1, characterized in that the first end of the insertion tube (6) comprises two diagonally symmetrical frame slots for receiving the frame (1a) of the intrauterine system (1). 
Aplikator za umetanje prema zahtjevu 1, naznačen time što prvi kraj cjevčice za umetanje (6) obuhvaća dva dijagonalno simetrična ležišta (20) prilagođeno za primanje okvira (14) intrauterinog sustava.
the pharmaceutical preparation in the suitable container is an aqueous pharmaceutical solution comprising 20mg/ml glatiramer acetate and 40mg/ml mannitol, or 40mg/ml glatiramer acetate and 40mg/ml mannitol, or 
farmaceutski pripravak u prikladnom spremniku jest vodena farmaceutska otopina koja sadrži 20mg/ml glatiramer acetata i 40mg/ml manitola, ili 40mg/ml glatiramer acetata i 40mg/ml manitola, ili
The compound for use according to claim 4, where the daily dose is 50-100 mg. 
Spoj za uporabu prema zahtjevu 4, naznačen time, da dnevna doza iznosi od 50 do 100 meg.
to 99 % by weight of a vegetable or animal fat with a melting point above 20 °C; and one or more herbs, spices and flavour enhancers, wherein the herbs, spices and flavor enhancers are coated with oil. 
66 do 99%, težinski, biljne ili životinjske masti s talištem iznad 20 *C; 1 ili. jednog ili više začinskog bilja, začina i pojačivača okusa, gdje se začinsko bilje, začine i pojačivače okusa prekrije uljem.
instructions for separate administration of said first and second pharmaceutical compositions to a patient, wherein said first and second pharmaceutical compositions are contained in separate containers and said second pharmaceutical composition is administered to a patient requiring neutralization or partial neutralization of dabigatran or 1-O-acylglucuronide of dabigatran. 
(c) upute za odvojenu primjenu prvog i drugog farmaceutskog sastava kod pacijenta; pri čemu se navedeni prvi i drugi farmaceutski sastav nalaze u odvojenim spremnicima, dok se drugi farmaceutski sastav upotrebljava za primjenu kod pacijenta kojemu je potrebna neutralizacija ili djelomična neutralizacija dabigatrana ili 1-O-acilglukuronida od dabigatrana.
In one embodiment, one of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the seed region of the antisense strand. In one embodiment, the antisense strand comprises a universal base at the mismatched nucleotide. 
RNAi sredstvo ili farmaceutski pripravak za uporabu prema zahtjevu 12, naznačeno time da (a) jedna od 3 nukleotidne razlike u nukleotidnoj sekvenci protusmjernog lanca je nukleotidna neusklađenost u sjemenskoj regiji protusmjernog lanca, pri čemu protusmjerni lanac poželjno sadrži univerzalnu bazu na neusklađenom nukleotidu; i/ili
A method according to claim 10 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
B2 agonist za uporabu prema zahtjevu 18 naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom.
Door closing hinge according to claim 1 or 2, wherein said at least one first and second planes (π', π", π"') are reciprocally parallel. 
Spojnica za zatvaranje vrata prema zahtjevu 1 ili 2, gdje su barem jedna prva i druga ravnina (1', m", 1 paralelne.
The combination therapy for use according to claim 10, wherein the interferon-beta 1a is to be administered once a week. 
Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 10, naznačena time što interferon-B1a treba primijeniti jednom tjedno.
suspending the dried precipitate obtained at step b) of claim 1 in pure ethanol, homogenizing and maintaining the homogenate under constant stirring for 24 h at room temperature in the dark; 
suspendiranje osušenog taloga dobivenog u koraku b) u skladu s patentnim zahtjevom čistom etanolu, homogeniziranje i održavanje homogenata pod konstantnim miješanjem na sobnoj temperaturi u mraku u trajanju od 24 h;
The method as in embodiment 3, wherein the second pre-determined distance (D1, D2) essentially corresponds to surface portions where the surface (2) is to be cut and/or where locking systems will be formed. 
Postupak prema zahtjevu 3, naznačen time što druga unaprijed određena udaljenost (D1, D2) uglavnom odgovara dijelovima površine gdje se površina (2) treba odrezati i/ili gdje će se oblikovati sustavi za blokiranje.
MMVF according to claim 10, wherein the MMVF have a composition comprising the following oxides, expressed by wt of oxides: 
MMF sukladno patentnom zahtjevu 10, naznačeno time da MMVEF ima spoj koji sadrži slijedeće okside, izraženo eksprimiranom težinom oksida:
Idebenone for use according to claim 9, wherein the glucocortocosteroids are selected from 6a-methylprednisolone-21 sodium succinate and deflazacort. 
Ibedenon za upotrebu prema 9. patentnom zahtjevu, naznačen time da su odabrani glukokortikosteroidi 6ά-metilprednizolon-21 natrij sukcinat i deflazocort.